N-<3.4-Bis-(4-chlor-phenyl)-1-methyl-propyl>-fumaramidsaeure | 15445-93-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: N-<3.4-Bis-(4-chlor-phenyl)-1-methyl-propyl>-fumaramidsaeure
• 英文别名: Benzmalecenum；(E)-4-[3,4-bis(4-chlorophenyl)butan-2-ylamino]-4-oxobut-2-enoic acid
• CAS: 15445-93-9
• 化学式: C₂₀H₁₉Cl₂NO₃
• 分子量: 392.282
• InChiKey: NKPCAAMLVDTZOB-ZHACJKMWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• Soft tertiary amine esters of bio-affecting carboxylic acids, processes for preparing and a pharmaceutical composition containing the same
  申请人：Merck & Co., Inc.

  公开号：EP0051278A1

  公开（公告）日：1982-05-12

  Derivatives of known bio-affecting carboxylic acids, their non-toxic pharmaceutically acceptable acid addition salts and N-oxides as well as processes for preparing those novel derivatives are disclosed. Those derivatives having the wherein R-COO- is the acyloxy residue of a bio-affecting monocarboxylic acid; Y and Y' are each hydrogen or alkyl; n is zero or one; R1 and R2 are each inter alia alkyl, alkenyl, aryl, cycloalkyl, cycloalkenyl, aralkyl or alkaryl; and R3 is inter alia hydrogen; orthe structural formula wherein -OOC-R'-COO- is the di(acyloxy) residue of a bio-affecting dicarboxylic acid.

  本研究公开了已知具有生物效应的羧酸的衍生物、它们的无毒药学上可接受的酸加成盐和 N-氧化物，以及制备这些新型衍生物的工艺。这些衍生物具有 其中 R-COO- 是生物效应单羧酸的酰氧基残基；Y 和 Y'各自是氢或烷基；n 是零或一；R1 和 R2 除其他外各自是烷基、烯基、芳基、环烷基、环烯基、芳烷基或烷芳基；以及 R3 除其他外是氢；或结构式为 其中-OOC-R'-COO-是具有生物效应的二羧酸的二（酰氧基）残基。
• Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
  申请人：Counts David F.

  公开号：US10463611B2

  公开（公告）日：2019-11-05

  The present disclosure provides a once-daily water-soluble pharmaceutically active formulation for oral administration. In certain embodiments, the composition comprises a water-soluble pharmaceutically active organic compound incorporated into a small particulate, each particulate having a core of the water-soluble pharmaceutically active organic compound or an acceptable salt thereof in reversible association with a pharmaceutically acceptable drug-binding polymer. The core of the composition being surrounded by an insoluble water permeable membrane that is capable of delaying the dissolution of the pharmaceutically active compound therewithin and providing for extended release of the pharmaceutically active compound. In some embodiments, the formulation of the invention are designed to extend release of the pharmaceutically active organic compound for about 3 hours to about 8 hours, thereby enabling preparation of an extended release formulation for any pharmaceutically active compound with a half-life of from about 16 hours to about 21 hours.

  本公开提供了一种用于口服的每日一次水溶性药用活性制剂。在某些实施方案中，该组合物包括掺入小颗粒中的水溶性药用活性有机化合物，每个颗粒都有一个水溶性药用活性有机化合物或其可接受盐的核心，该核心与药学上可接受的药物结合聚合物可逆结合。组合物的核心由不溶性透水膜包围，该膜能够延迟其中的药用活性化合物的溶解，并延长药用活性化合物的释放时间。在某些实施方案中，本发明的制剂可将药用活性有机化合物的释放时间延长约 3 小时至约 8 小时，从而能够制备半衰期为约 16 小时至约 21 小时的任何药用活性化合物的缓释制剂。
• LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY
  申请人：Scidose, Llc

  公开号：EP1954244A1

  公开（公告）日：2008-08-13
• CONTROLLED ABSORPTION WATER-SOLUBLE PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND FORMULATION FOR ONCE-DAILY ADMINISTRATION
  申请人：STI Pharma, LLC

  公开号：EP2717860A1

  公开（公告）日：2014-04-16